Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedule of Fair Value Measurements

As of December 31, 2018	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total
Investments in Equity Securities
Adhera Therapeutics – Convertible Series E Preferred Shares	$	-	$	-	$	-	$	1,769,300	$	1,769,300
	$	-	$	-	$	-	$	1,769,300	$	1,769,300

Schedule of Changes in Fair Value Measurements

The change in the value of the investment, under level 3 of the Fair Value Measurement, is shown as under:

	Year ended
	December 31, 2019			December 31, 2018
Opening Balance	$	1,769,300		$	-
Value introduced		-			1,769,300
Write off value of investment		(1,769,300	)		-
Closing balance	$	-		$	1,769,000

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive:

	Year ended
	December 31, 2019		December 31, 2018
Convertible notes		10,000,000		-
Stock options		6,145,044		6,785,617
Warrants		19,515,787		24,380,893
Potentially dilutive securities		35,660,831		31,166,510